<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081066</url>
  </required_header>
  <id_info>
    <org_study_id>C13-20</org_study_id>
    <secondary_id>2013-A00798-37</secondary_id>
    <nct_id>NCT02081066</nct_id>
  </id_info>
  <brief_title>Identification of CETP as a Marker of Atherosclerosis</brief_title>
  <acronym>CETP-ATHERO</acronym>
  <official_title>Relationship Between Endogenous CETP Activity and Atherosclerosis Distribution in Patients With High Cardiovascular Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reverse cholesterol transport (RCT) pathway, which involves the centripetal movement of&#xD;
      free cholesterol from peripheral tissues, including the vessel wall, to the liver represent&#xD;
      the primary mechanism by which HDL protects against atherosclerosis and by which it may&#xD;
      induce plaque regression. Recent data reveal that the capacity of HDL to efflux cholesterol&#xD;
      from macrophages, a metric of HDL function reflecting the initial step of the RCT, is&#xD;
      clinically relevant, displaying a strong inverse association with both carotid intima-media&#xD;
      thickness and the severity of angiographic CAD; such observations were independent of HDL-C&#xD;
      levels.&#xD;
&#xD;
      In human, the Cholesteryl Ester Transfer Protein (CETP), represents a key protein of the RCT&#xD;
      pathway and mediates redistribution of neutral lipids between lipoproteins, has been&#xD;
      identified as a potential therapeutic target against atherosclerosis. It is known that CETP&#xD;
      activity correlates with HDL-C levels and represents a key modulator of the ability of whole&#xD;
      plasma to mediate free cholesterol efflux from human macrophages.&#xD;
&#xD;
      Recent studies showed that 23% of endogenous plasma CETP activity variability is explained by&#xD;
      plasma LDL-C (12.0%), HDL-C (6.4%) and TG (4.4%) whereas sex and BMI accounted together for&#xD;
      only 0.7% of its variability. Scoring patients for cardiovascular risk on the basis of their&#xD;
      plasma lipid levels (TC, TG, LDL-C and HDL-C), revealed that patients with high&#xD;
      cardiovascular risk (score ≥3) displayed a mean endogenous plasma CETP activity above 34%.&#xD;
      Therefore plasma CETP activity represents a potent indicator of cardiovascular risk in&#xD;
      patients with metabolic disorders since it integrates major independent risk factors.&#xD;
&#xD;
      The objective of this study is to decipher the relationship between CETP, HDL efflux capacity&#xD;
      and the development of atherosclerosis in humans in order to identify CETP as a potent&#xD;
      biomarker of atherosclerosis distribution.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2014</start_date>
  <completion_date type="Actual">September 2020</completion_date>
  <primary_completion_date type="Actual">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endogenous CETP activity</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>carotid intima-media thickness</measure>
    <time_frame>day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary calcium score</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma efflux capacity from human macrophage</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL genetic variant</measure>
    <time_frame>Day1</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>patients with cardiovascular risk factors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cardiovascular risk factors</intervention_name>
    <arm_group_label>patients with cardiovascular risk factors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent prior to initiation of the study&#xD;
&#xD;
          -  Men and women aged 18 or more years&#xD;
&#xD;
          -  Patients displaying at least one abnormal plasma lipid parameter and/or receiving a&#xD;
             lipid-lowering therapy unchanged for at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current significant renal disease, including: nephrotic syndrome; chronic renal&#xD;
             failure and/or serum creatinine &gt;1.7 x upper limit of the reference range (ULRR)&#xD;
&#xD;
          -  Uncontrolled hypothyroidism defined as TSH &gt;2 x ULRR&#xD;
&#xD;
          -  Active hepatobiliary disease, including chronic hepatitis B or hepatitis C infection&#xD;
             (confirmed by serology); or an aspartate aminotransferase (AST/SGOT) or alanine&#xD;
             aminotransferase (ALT/SGPT) &gt;3.0 x ULRR&#xD;
&#xD;
          -  Any prior history of malignancy or current cancer&#xD;
&#xD;
          -  Current chronic or acute inflammatory syndrome defined as CRP&gt;10 mg/l&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryse Guerin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inserm Umrs1166</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>March 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

